Heterogeneity of antibodies to β2-glycoprotein 1 from patients with systemic lupus erythematosus

Lupus

Volumn 13, Issue 3, 2004, Pages 182-187

  Cabral, Antonio R ^a   Cabiedes, J ^a   Alarcon Segovia D ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antibodies to human 2 glycoprotein 1; Antiphospholipid antibodies; Antiphospholipid syndrome; Systemic lupus erythematosus

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; GLYCOPROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC HETEROGENEITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PROBABILITY; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 1842782589     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu531oa     Document Type: Article

References (22)

1. 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
2. 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 1997; 24: 1545-1551.
3. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
4. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21: 275-286.
5. Delezé M, Oria CV, Alarcón-Segovia D. Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. J Rheumatol 1988; 15: 611-615.
6. 2-glycoprotein-I for reactivity of antibodies from patients with primary antiphospholipid syndrome. J Autoimmunity 1992; 5: 787-801.
7. Alarcón-Segovia D, Delezé M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-365.
8. Zilversmit DB, Davis AK. Microdetermmation of plasma phospholipids by trichloroacetic acid precipitation. J Lab Clin Med 1950; 35: 155-160.
9. Mangold KH. Aliphatic lipids. In Stahl E, ed. Thin layer chromatography New York: Springer-Verlag, Inc., 1969: 363-420.
10. 2-glycoprotein-I and their unmasking by heat. Clin Exp Rheumatol 1994; 12: 123-127.
11. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa T, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease (Letter). Lancet 1990; 336: 177-178.
12. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462.
13. 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-960.
14. 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101: 472-481.
15. 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1997; 35: 1239-1243.
16. Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. Prevalence of antibodies to β2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol 2000; 27: 2833-2837.
17. 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-659.
18. 2GP-I in alternation of anticardiolipin binding. Intl Immunol 1991; 3: 1217-1221.
19. Damosieaux J, Wijffels M, van Papmpus L, Tervaert Cohen JW, van Paesen P. The anti-phospholipid/cofactor syndrome: the result of routine screening for antibodies to beta-2-glycoprotein-I upon suspicion of the APS. Lupus 2002; 11: 581.
20. Levy RA, Gharavi AE, Sammaritano LR, Habina L, Qamar T, Lockshin MD. Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. J Rheumatol 1990; 17: 1036-1041.
21. Alarcón-Segovia D, Cabral AR. The antiphospholipid antibody syndrome: clinical and serological aspects. In Alarcón GS, Catoggio LJ, ed. Balliéres' clinical rheumatology. London: Bailliere Tindall, 2000: 139-150.
22. Inanc M, Radway-Bright EL, Isenberg DA. β2-glycoprotein I and anti-β2-glycoprotein I antibodies: where are we now? Br J Rhumatol 1997; 36: 1247-1257.